Lantern PharmaLTRN
LTRN
About: Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Employees: 24
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2,280% more call options, than puts
Call options by funds: $119K | Put options by funds: $5K
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
7% more capital invested
Capital invested by funds: $8M [Q4 2024] → $8.59M (+$590K) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.71% less ownership
Funds ownership: 23.17% [Q4 2024] → 22.46% (-0.71%) [Q1 2025]
3% less funds holding
Funds holding: 32 [Q4 2024] → 31 (-1) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$25
720%
upside
Avg. target
$25
720%
upside
High target
$25
720%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Chad Messer | 720%upside $25 | Buy Initiated | 2 Apr 2025 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
DALLAS--(BUSINESS WIRE)--ATRT data presented at SNO Pediatric 2025.
Neutral
Seeking Alpha
1 month ago
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Panna Sharma - President & CEO David Margrave - CFO Conference Call Participants Operator Good morning, and welcome to our First Quarter 2025 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.
Neutral
Business Wire
1 month ago
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
DALLAS--(BUSINESS WIRE)--Q1 2025 Lantern Pharma Earnings (LTRN).
Neutral
Business Wire
1 month ago
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that the U.S. Food and Drug Administration (FDA) has cleared the amendment to its Investigational New Drug (IND) application to initiate a Phase 1b/2 clinical trial of LP-184 in a genomically defined patient population of non-small cell lung cancer (NSCLC) where there is a need to improve.
Neutral
Business Wire
1 month ago
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
DALLAS--(BUSINESS WIRE)--Q1 Earnings Call Save The Date.
Neutral
Business Wire
1 month ago
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR®, today announced that it has received clearance of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial for LP-184 in Triple Negative Breast Cancer. This achievement builds on the previous regulatory momentum including Orphan Drug.
Neutral
Seeking Alpha
2 months ago
Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 AM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Conference Call Participants Operator Good afternoon, and welcome to our Fourth Quarter and Year End 2024 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.
Neutral
Business Wire
2 months ago
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on its portfolio of AI-driven drug candidates, the RADR® platform for precision oncology drug.
Neutral
Business Wire
2 months ago
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Q4 & Fiscal Year 2024 Earnings Call Save The Date.
Neutral
Business Wire
3 months ago
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced the publication of its PCT patent application (PCT/US2024/019851) covering a novel machine learning solution for predicting blood-brain barrier (BBB) permeability. The application received a favorable PCT search report indicating no significant prior.
Charts implemented using Lightweight Charts™